Core Viewpoint - The popular brand "Mian Mima" sanitary napkins is facing health concerns due to high levels of thiourea detected in multiple batches of its products, raising questions about consumer safety and regulatory compliance [1][5][24]. Group 1: Product and Brand Overview - "Mian Mima" was founded by popular livestreamer Xin Ba in 2017 and has reportedly achieved cumulative sales of 3.33 billion yuan over eight years [3][21]. - The brand claims to use tea polyphenol chips in its sanitary napkins, marketed for their antioxidant properties [1][3]. Group 2: Detection of Thiourea - Multiple batches of "Mian Mima" sanitary napkins, including the tea oxygen series, have been found to contain thiourea, with one sample showing a concentration as high as 16,653.4679 μg/g [1][3][5]. - A report indicated that 7 out of 10 samples tested positive for thiourea, with levels ranging from 3,732.2022 μg/g to 6,210.3620 μg/g [3][14]. Group 3: Health Implications - Thiourea is classified as a hazardous chemical and a potential carcinogen, with long-term exposure linked to various health risks, including thyroid dysfunction and reproductive toxicity [5][6][11]. - Consumer feedback has revealed a concerning number of health issues, including thyroid cancer and other related symptoms, among users of "Mian Mima" products [9][10]. Group 4: Regulatory and Industry Context - The sanitary napkin industry lacks specific regulations for the components used in sanitary napkin chips, creating a regulatory gray area [21][24]. - The new national standard for disposable sanitary products, effective July 1, 2024, aims to clarify regulations regarding additives, including prohibiting substances like thiourea [24][25].

Core Viewpoint - Toxin Pharmaceutical (301089.SZ) announced an investment of 10 million yuan in Jiangsu Jinsan Biotechnology Co., Ltd., acquiring a 1.75% stake, aiming to leverage its technological advantages in the field of chemical and synthetic biology [1] Group 1: Investment Details - The investment consists of 223,400 yuan added to registered capital, with the remainder allocated to capital reserves [1] - Following the investment, Toxin Pharmaceutical will hold a direct stake of 1.75% in Jinsan Biotechnology [1] Group 2: Company Overview - Jinsan Biotechnology specializes in the research, production, and sales of synthetic biological products, focusing on the development and industrial application of ergothioneine [1] - The company has achieved breakthroughs in the entire chain of technology, including strain construction, fermentation, purification, and engineering-scale production of high-purity ergothioneine [1] Group 3: Market Potential - The market for ergothioneine terminal products in China is projected to reach 1.57 billion yuan by 2024, with 60% used in skincare and nearly 30% in health food [3] - The global ergothioneine raw material market is expected to grow from 6.3 million USD in 2024 to 16.1 million USD by 2031, with a CAGR exceeding 14% [3] Group 4: Controversies - Ergothioneine has faced controversies, including claims by a prominent biologist labeling it as a "fake drug," which has been disputed by related companies citing scientific backing [4]

Core Insights - The report by Beijing Yihe International Information Consulting Co., Ltd. provides an in-depth analysis of the astaxanthin market, focusing on both global and Chinese markets, with projections for 2025 [1][4] - The report is designed for investors, corporate decision-makers, research institutions, and government policymakers, offering insights into market dynamics, competitive landscape, and future expectations [4][9] Market Overview - The astaxanthin market is becoming increasingly competitive, with major players including Fuji Chemical from Japan, Astaxanthin from the USA, and various biotechnology companies from China [4][5] - The market is expected to reach several billion dollars by 2025, driven by rising health awareness and the growing popularity of natural ingredients [7][8] Industry Chain - The astaxanthin industry chain includes multiple stages: upstream involves the capture and farming of marine organisms, midstream focuses on extraction and processing, and downstream applications span food, health supplements, and cosmetics [7][8] - The report will explore the current status and future development of each segment of the industry chain [7] Regional Insights - The primary markets for astaxanthin are North America, Europe, and the Asia-Pacific region, with North America being the largest consumer market due to high demand for health foods [8] - The Asia-Pacific region is noted as the fastest-growing market, driven by increasing demand for health supplements as living standards improve [8] Regulatory Environment - China's regulatory environment plays a crucial role in the development of the astaxanthin market, with increasing government support for natural ingredient health products [9] - The report will analyze relevant policies and regulations in China to guide companies in market entry and product promotion [9]